Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial(Nature Medicine, 10.1038/s41591-024-03485-7)

Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Beksac, M., Maiolino, A., Takamatsu, H., Perrot, A. & Turgut, M. & 11 others, Ahmadi, T., Liu, W., Wang, J., Chastain, K., Vermeulen, J., Krevvata, M., Lopez-Masi, L., Carey, J., Rowe, M., Carson, R. & Zweegman, S., 2025, (E-pub ahead of print) In: Nature medicine.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study

Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Beksac, M., Maiolino, A., Takamatsu, H., Perrot, A. & Turgut, M. & 11 others, Ahmadi, T., Liu, W., Wang, J., Chastain, K., Vermeulen, J., Krevvata, M., Lopez-Masi, L., Carey, J., Rowe, M., Carson, R. & Zweegman, S., 2025, (E-pub ahead of print) In: Nature medicine. 53.

Research output: Contribution to journal › Article › Academic › peer-review

Factors and Considerations in No-Treatment Decisions in Patients With Key Hematological Malignancies: A Nationwide, Population-Based Study in the Netherlands

Zijlstra, M., Snijders, R. A. H., de Boer, F., Chamuleau, M. E. D., Fransen, H. P., Oerlemans, S., van der Padt-Pruijsten, A., Posthuma, E. F. M., Visser, O., Zweegman, S., Raijmakers, N. J. H. & Dinmohamed, A. G., May 2025, In: European journal of haematology. 114, 5, p. 872-882 11 p.

Research output: Contribution to journal › Article › Academic › peer-review

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera: CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Beauverd, Y., Ianotto, J.-C., Thaw, K. H., Sobas, M., Sadjadian, P., Curto-Garcia, N., Shih, L.-Y., Devos, T., Krochmalczyk, D., Galli, S., Bieniaszewska, M., Seferynska, I., McMullin, M. F., Armatys, A., Spalek, A., Waclaw, J., Zdrenghea, M. T., Legros, L., Girodon, F. & Lewandowski, K. & 26 others, Bellosillo, B., Samuelsson, J., Abuin Blanco, A., Cony-Makhoul, P., Collins, A., James, C., Kusec, R., Lauermannova, M., Noya, M. S., Skowronek, M., Szukalski, L., Szmigielska-Kaplon, A., Wondergem, M., Dudchenko, I., Gora-Tybor, J., Laribi, K., Kulikowska de Nałęcz, A., Demory, J.-L., le Dû, K., Zweegman, S., Besses Raebel, C., Skoda, R. C., Giraudier, S., Griesshammer, M., Kiladjian, J.-J. & Harrison, C. N., 2025, (E-pub ahead of print) In: Leukemia.

Research output: Contribution to journal › Article › Academic › peer-review

The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy

Kaplan, Z. L. R., van Leeuwen, N., van Klaveren, D., Eijkenaar, F., Visser, O., Posthuma, E. F. M., Zweegman, S., Huls, G., van Rhenen, A., Blijlevens, N. M. A., Cornelissen, J. J., van de Loosdrecht, A. A., Pruijt, J. H. F. M., Levin, M. D., Hoogendoorn, M., Lemmens, V. E. P. P., Lingsma, H. F. & Dinmohamed, A. G., 1 Feb 2025, In: ESMO open. 10, 2, 104152.

Research output: Contribution to journal › Article › Academic › peer-review